Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy

被引:134
|
作者
Lilleby, W
Fosså, SD [1 ]
Waehre, HR
Olsen, DR
机构
[1] Norwegian Radium Hosp, Dept Radiotherapy & Oncol, N-0310 Oslo, Norway
[2] Norwegian Radium Hosp, Dept Surg Oncol, N-0310 Oslo, Norway
[3] Norwegian Radium Hosp, Dept Phys Med, N-0310 Oslo, Norway
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1999年 / 43卷 / 04期
关键词
prostate cancer; radiation therapy; prostatectomy; quality of life; long-term morbidity;
D O I
10.1016/S0360-3016(98)00475-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To assess morbidity, side effects, and quality of life (QoL) in patients treated for localized prostate cancer with curative aim. Methods and Materials: This descriptive cross-sectional study comprises 154 patients who had undergone definitive radiotherapy (RAD) and 108 patients with radical prostatectomy (PRECT) at the Norwegian Radium Hospital during 1987-1995. At least 1 year after treatment the patients completed several questionnaires assessing quality of life (European Organization for Research and Treatment of Cancer QLQ-C30 instrument [EORTC QLQ-C30]), lower urinary tract symptoms (LUTS): International Prostate Symptom Score (IPSS), or sexuality (selected questions from the Psychosocial Adjustment to Illness Scale [PAIS]). Urinary incontinence and bowel distress were evaluated by ad hoc constructed questionnaires. A control group (OBS) consisted of 38 patients following the watch-and-wait policy. Results: Twenty percent of the patients from the RAD Group had moderate (14%) or severe (6%) LUTS as compared to 12% in the PRECT group. However, 35% of men from the latter group reported moderate to severe urinary incontinence. "Overall" sexuality was moderately or severely impaired in 71% of the PRECT and 50% of the RAD patients. In the former group high age was correlated with erectile impotency (p < 0.001). In the RAD comorbidity was associated with erectile impotency (p < 0.001). Between 13-38% of the patients recorded moderate or severe bowel distress (blood per rectum: 13%; bowel cramps: 26%; flatulence: 38%), without significant differences comparing patients who had received conventional small 4-field box radiotherapy and patients who had undergone strictly conformal radiotherapy. Despite malignancy and/or treatment-related morbidity, QoL was comparable in both groups with respectively 9% and 6% RAD and PRECT patients, reporting moderately or severely impaired QoL. In the multivariate analysis physical function, emotional function and fatigue were significantly correlated with QoL, whereas sexuality, lower urinary symptoms, and urinary incontinence correlated with QoL only in the univariate analysis. Conclusion: In spite of considerable malignancy and/or treatment-related morbidity QoL was good or only slightly impaired in the majority of patients with localized prostate cancer who presented with stable disease > 1 year after definitive radiotherapy or radical prostatectomy with no difference as compared to the age-matched normal population. Clinicians should be aware of the fact that general QoL dimensions (physical function, emotional function, fatigue) are as a rule of greater significance for QoL than sexuality and lower urinary tract symptoms. (C) 1999 Elsevier Science Inc.
引用
收藏
页码:735 / 743
页数:9
相关论文
共 50 条
  • [1] Long-term Continence Outcomes in Men Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer
    Prabhu, Vinay
    Sivarajan, Ganesh
    Taksler, Glen B.
    Laze, Juliana
    Lepor, Herbert
    EUROPEAN UROLOGY, 2014, 65 (01) : 52 - 57
  • [2] Quality of life in men with localized prostate cancer treated by radical prostatectomy or radiotherapy
    Rodgers, JK
    Sawhney, R
    Chaudhary, U
    Bissada, NK
    ARCHIVES OF ANDROLOGY, 2006, 52 (02): : 129 - 133
  • [3] Salvage radical prostatectomy: Quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer
    Sanderson, Kristin M.
    Penson, David F.
    Cai, Jie
    Groshen, Susan
    Stein, John P.
    Lieskovsky, Gary
    Skinner, Donald G.
    JOURNAL OF UROLOGY, 2006, 176 (05) : 2025 - 2031
  • [4] Intensity-modulated radiotherapy versus radical prostatectomy in patients with localized prostate cancer: long-term follow-up
    Merino, Tomas
    Francisco, Ignacio F. San
    Rojas, Pablo A.
    Bettoli, Piero
    Zuniga, Alvaro
    Besa, Pelayo
    BMC CANCER, 2013, 13
  • [5] Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer
    Ervandian, Maria
    Hoyer, Morten
    Petersen, Stine Elleberg
    Sengelov, Lisa
    Hansen, Steinbjorn
    Kempel, Mette Moe
    Petersen, Peter Meidahl
    Borre, Michael
    SCANDINAVIAN JOURNAL OF UROLOGY, 2017, 51 (06) : 457 - 463
  • [6] Longitudinal study of quality of life in patients with localized prostate cancer undergoing radiotherapy
    Monga, U
    Kerrigan, AJ
    Thornby, J
    Monga, TN
    Zimmermann, KP
    JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT, 2005, 42 (03) : 391 - 399
  • [7] The Effects of Radiotherapy on the Quality of Life in Localized Prostate Cancer Patients
    Guler Avci, Gulhan
    Yucel, Birsen
    Erdis, Eda
    TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2020, 35 (03): : 242 - 249
  • [8] Determinants of long-term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer
    Bradley, EB
    Bissonette, EA
    Theodorescu, D
    BJU INTERNATIONAL, 2004, 94 (07) : 1003 - 1009
  • [9] Definitive Conformal Radiotherapy for Localized Prostate Cancer: A Long-term Follow-up Study
    Deichmueller, Cordula M. C.
    Wegener, Gerd
    Karstens, Johann H.
    Bruns, Frank
    ANTICANCER RESEARCH, 2009, 29 (07) : 2627 - 2634
  • [10] Intensity-modulated radiotherapy versus radical prostatectomy in patients with localized prostate cancer: long-term follow-up
    Tomás Merino
    Ignacio F San Francisco
    Pablo A Rojas
    Piero Bettoli
    Álvaro Zúñiga
    Pelayo Besa
    BMC Cancer, 13